Synthesis, Pharmacological, and Hematological Evaluation of Cinnamaldehyde-Derived Schiff Base
Clicks: 2
ID: 311595
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #248 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: Cinnamaldehyde (trans-cinnamaldehyde) and para-aminophenol, (Z)-4-((4-(dimethylamino)benzylidene)-amino)-phenol were used in the synthesis of Schiff base. This study aimed to synthesize and quantify derivatives of para-aminophenol and Cinnamaldehyde Schiff bases derivative, characterize and determine the toxicity and pharmacological properties, as well as potential binding affinity on specific cellular enzymes and proteins.
Methods: The compound was synthesized via microwave-assisted condensation, achieving a high yield of 95.4%, and characterized using physicochemical analysis, thin-layer chromatography
(Rf = 0.69 ± 0.08 in methanol), ¹H NMR (nuclear magnetic resonance), ¹³C NMR, a high-resolution mass spectrometer, and UV-visible spectrophotometry (λmax = 260 nm). Biological evaluations included antimicrobial, acute toxicity (LD₅₀), analgesic, and hematological profiling such as hemoglobin concentration, packed cell volume, platelet count, and differential leukocyte distribution.
Results: The compound demonstrated moderate antimicrobial activity, with zones of inhibition against Escherichia coli (13 mm at 62.5 μg/mL) and Candida albicans (13 mm at 500 μg/mL). The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were found to be 250 μg/mL for E. coli and 62.5 μg/mL (MIC) for C. albicans. Analgesic evaluation revealed that the test compound significantly increased reaction time in mice, particularly at 60- and 90-minute post-administration, with effects comparable to pethidine (at a dose of 12 mg/kg). ANOVA confirmed significance (P = 0.0002), while no significant difference was found between the test compound and the standard at peak effect (P = 0.80). LD₅₀ of 1265 mg/kg suggests a moderate toxicity profile. Hematological analysis showed dose-dependent changes in white blood cell and red blood cell counts. In silico docking studies demonstrated a strong binding affinity to key antimicrobial and analgesic targets, including Cyclooxygenase-2 (COX-2) (−7.52 kcal/mol) and 5FSA (−7.65 kcal/mol), which supports the in vivo results.
Conclusions: These findings suggest that the synthesized Schiff base compound has promising potential as a dual-action antimicrobial and analgesic agent, with a relatively safe hematological profile and good molecular interactions at target sites.
| Reference Key |
bunu2025synthesis
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Samuel J. Bunu, Oyeintonbara Miediegha, Ruth E. Clement, Deghinmotei Alfred-Ugbenbo, Vincent O. Imieje, Cyril O. Usifoh |
| Journal | Yemen Journal of Medicine |
| Year | 2025 |
| DOI |
10.63475/yjm.v4i3.0174
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.